/EINPresswire.com/ -- OTTAWA, ONTARIO -- (Marketwired) -- 03/24/16 -- Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) will hold a public hearing with respect to allegations that Baxalta Canada Corporation failed to provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicine Regulations. The proceeding relates to the medicine Oncaspar, which is sold in Canada under Health Canada's Special Access Programme and is used in the treatment of patients with Acute Lymphoblastic Leukemia.

The purpose of the hearing is to receive evidence and argument of Board Staff, Baxalta Canada Corporation, and any interveners regarding allegations that Baxalta Canada Corporation is in breach of its reporting requirements. The date, time, and location of the public hearing will be set and confirmed at a later date.

Those wishing to participate in this proceeding must apply to the Board for leave to intervene by May 2, 2016. For more information on the application process, please contact:

Guillaume Couillard
Director, Board Secretariat
Patented Medicine Prices Review Board
Box L40, 333 Laurier Avenue West, Suite 1400
Ottawa, Ontario K1P 1C1
Telephone: 613-954-8299
Fax: 613-952-7626
E-mail: Guillaume.Couillard@pmprb-cepmb.gc.ca

Quick Facts

--  The Patented Medicine Prices Review Board is an independent quasi-
    judicial body that protects the interests of Canadian consumers by
    ensuring the prices of patented medicines sold in Canada are not
    excessive, and provides stakeholders with price, cost, and utilization
    information to help them make timely and knowledgeable drug pricing,
    purchasing, and reimbursement decisions.
--  Patentees must file price and sales information with the Patented
    Medicine Prices Review Board at introduction, and twice a year
    afterward, for each strength of each dosage form of each patented
    medicine sold in Canada.
--  Board Staff review the prices patentees charge for each individual
    patented drug product sold in Canadian markets on an ongoing basis to
    ensure their prices are not excessive.
--  If the Board Panel finds a patentee to be in breach of its reporting
    requirements, the Board Panel may order the patentee to provide the
    Patented Medicine Prices Review Board with the required pricing and
    sales information.

Related Products

--  Notice of Hearing
--  Notice of Application - Failure to File (PDF - 802 kb)

Additional Links

--  Patent Act (Justice Canada)
--  Patented Medicines Regulations (Justice Canada)
--  Status of Ongoing Proceedings (Patented Medicine Prices Review Board)

Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Sofie.McCoy-Astell@pmprb-cepmb.gc.ca

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.